{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:17:31Z","timestamp":1777299451950,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.bbapap.2014.03.006","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T10:06:35Z","timestamp":1395309995000},"page":"1104-1110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease"],"prefix":"10.1016","volume":"1844","author":[{"given":"Gerard","family":"Esteban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Allan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelouahid","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mattevi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Unzeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Marco-Contelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Binda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rona R.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbapap.2014.03.006_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.02.002","article-title":"Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease","volume":"97","author":"Xu","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0010","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1021\/jm020120c","article-title":"Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease","volume":"45","author":"Sterling","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2004.11.007","article-title":"Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders","volume":"26","author":"Youdim","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0022-3565(24)38924-4","article-title":"Multiple central nervous system targets for eliciting beneficial effects on memory and cognition","volume":"295","author":"Buccafusco","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0025","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.2174\/09298673113209990112","article-title":"Rationally designed multi-targeted agents against neurodegenerative diseases","volume":"20","author":"Geldenhuys","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0030","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00001756-200502080-00006","article-title":"Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease","volume":"16","author":"Venneri","year":"2005","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0040","first-page":"47","article-title":"Age-related changes of MAO-A and -B distribution in human and mouse brain","volume":"8","author":"Mahy","year":"2000","journal-title":"Neurobiology (Bp)"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0306-4522(94)90311-5","article-title":"Increased monoamine-oxidase-B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme autoradiography","volume":"62","author":"Saura","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2013.22.1.1","article-title":"Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline","volume":"22","author":"Youdim","year":"2013","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-008-9139-6","article-title":"The novel cholinesterase\u2013monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats","volume":"37","author":"Bar-Am","year":"2009","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138945012799499794","article-title":"Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment","volume":"13","author":"Weinreb","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0065","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138945012799499794","article-title":"Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective Monoamine Oxidase inhibitory activities for Alzheimer's Disease treatment","volume":"13","author":"Weinreb","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0070","first-page":"191","article-title":"A novel anti-Alzheimer's disease drug, ladostigil: neuroprotective, multimocbedal brain-selective monoamine oxidase and cholinesterase inhibitor","volume":"vol. 100","author":"Weinreb","year":"2011"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0163-7258(90)90064-9","article-title":"Biochemistry and genetics of monoamine-oxidase","volume":"47","author":"Weyler","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0085","doi-asserted-by":"crossref","first-page":"12684","DOI":"10.1073\/pnas.0505975102","article-title":"Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B","volume":"102","author":"De Colibus","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.2042-7158.1984.tb03004.x","article-title":"On the substrate specificities of 2 forms of monoamine oxidase","volume":"36","author":"Fowler","year":"1984","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/med.2610150406","article-title":"Selective inhibitors of monoamine-oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism","volume":"15","author":"Kalgutkar","year":"1995","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0100","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.2174\/1381612811319140004","article-title":"Inhibitor design for monoamine oxidases","volume":"19","author":"Ramsay","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0105","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/S0021-9258(19)42741-5","article-title":"Mitochondrial monoamine oxidase \u2013 inactivation by pargyline \u2013 adduct formation","volume":"249","author":"Chuang","year":"1974","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nsb732","article-title":"Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders","volume":"9","author":"Binda","year":"2002","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0115","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1021\/bi900413g","article-title":"Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases","volume":"48","author":"Edmondson","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0120","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1471-4159.1987.tb02895.x","article-title":"Turnover of brain monoamine-oxidase measured in vivo by positron emission tomography using L-[C-11]deprenyl","volume":"49","author":"Arnett","year":"1987","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0125","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.1021\/jm200853t","volume":"54","author":"Bolea","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2012.03.022","article-title":"Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine","volume":"52","author":"Samadi","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0135","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/j.1471-4159.2008.05326.x","article-title":"Anti-apoptotic effect of MAO-B inhibitor PF9601N[N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP(+)-treated SH-SY5Y human dopaminergic cells","volume":"105","author":"Sanz","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0140","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.bjp.0702600","article-title":"Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition","volume":"127","author":"Perez","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0145","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2174\/15672050113109990151","article-title":"The multipotent, permeable drug ASS234 inhibits A\u03b2 aggregation, possesses antioxidant properties and protects from A\u03b2-induced apoptosis","volume":"10","author":"Bolea","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.phrs.2010.09.001","article-title":"On the formation and nature of the imidazoline I(2) binding site on human monoamine oxidase-B","volume":"62","author":"McDonald","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0155","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0006-2952(03)00185-0","article-title":"Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure","volume":"65","author":"Hynson","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0160","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1016\/S0021-9258(17)38856-7","article-title":"Purification and properties of mitochondrial monoamine-oxidase type-A from human-placenta","volume":"260","author":"Weyler","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0165","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/prep.2000.1309","article-title":"High-level expression of human liver monoamine oxidase B in Pichia pastoris","volume":"20","author":"Newton-Vinson","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0170","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0175","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S0021-9258(18)69497-9","article-title":"A rapid spectrophotometric assay of monoamine oxidase based on the rate of disappearance of kynuramine","volume":"235","author":"Weissbach","year":"1960","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0180","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1021\/bi00232a038","article-title":"Kinetic mechanism of monoamine oxidase-A","volume":"30","author":"Ramsay","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0185","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/abio.1997.2391","article-title":"A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases","volume":"253","author":"Zhou","year":"1997","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0190","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/nprot.2006.402","article-title":"A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes","volume":"1","author":"Holt","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0195","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/S0021-9258(18)50153-8","article-title":"Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase","volume":"237","author":"Kitz","year":"1962","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0200","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejps.2005.07.005","article-title":"Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol","volume":"26","author":"Yang","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0205","doi-asserted-by":"crossref","first-page":"23973","DOI":"10.1074\/jbc.R200005200","article-title":"Structure\u2013function relationships in flavoenzyme-dependent amine oxidations. A comparison of polyamine oxidase and monoamine oxidase","volume":"277","author":"Binda","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0210","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1107\/S090744499900846X","article-title":"Integration of macromolecular diffraction data","volume":"55","author":"Leslie","year":"1999","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0215","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1107\/S0907444994003112","article-title":"The CCP4 suite \u2014 programs for protein crystallography","volume":"50","author":"Bailey","year":"1994","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0220","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1107\/S0907444911007281","article-title":"Presenting your structures: the CCP4mg molecular-graphics software","volume":"67","author":"McNicholas","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0225","series-title":"Monoamine Oxidases and Their Inhibitors","first-page":"65","article-title":"The pharmacology of selegiline","volume":"vol. 100","author":"Magyar","year":"2011"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0230","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11307-005-0016-1","article-title":"Translational neuroimaging: positron emission tomography studies of monoamine oxidase","volume":"7","author":"Fowler","year":"2005","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.bbapap.2014.03.006_bb0235","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/bi7019707","article-title":"Comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membrane-bound forms","volume":"47","author":"Upadhyay","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbapap.2014.03.006_bb0240","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/abio.1997.2392","article-title":"A one-step fluorometric method for the continuous measurement of monoamine oxidase activity","volume":"253","author":"Zhou","year":"1997","journal-title":"Anal. Biochem."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963914000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963914000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T03:27:48Z","timestamp":1746156468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570963914000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1570963914000569"],"URL":"https:\/\/doi.org\/10.1016\/j.bbapap.2014.03.006","relation":{},"ISSN":["1570-9639"],"issn-type":[{"value":"1570-9639","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbapap.2014.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}